Volume 8, Issue 4 (1-2022)                   nbr 2022, 8(4): 253-264 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Motaharinia M, Nabiuni M. Study of Cisplatin effects in comparison with Curcumin on Cdc42 gene expression in human Calu-6 lung carcinoma cell line. nbr 2022; 8 (4) :253-264
URL: http://nbr.khu.ac.ir/article-1-3407-en.html
Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran , devbiokharazmi@gmail.com
Abstract:   (2541 Views)
Lung carcinoma is the second most common type of cancer. Inefficiency of the current treatments and the undesirable side effects of chemotherapy drugs made the know-how of the treatment important. The purpose of this study is to investigate the synergic effect of curcumin and Cisplatin in comparison with the sole application of each treatment on Calu-6 cell line, an epithelial cell line of human lung carcinoma, and the expression of Cdc42 gene. The viability of Calu-6 was examined after 24- or 48-hour treatment with doses of 0.5 to 8 µg/ml of curcumin, 0.1 to 50 µg/ml of cisplatin and combined doses of curcumin and Cisplatin by MTT assay. To measure apoptosis and the expression of Cdc42 gene, flow cytometry and Real-Time PCR were utilized. Decrease of cell viability and induction of cell death were observed in the cells treated with 0.67 µg/ml of curcumin and 1.7 µg/ml of cisplatin (the lowest effective dose) and the combined treatment with the same doses of each drug after 24-hour treatments. The maximum rates of early and late apoptosis were related to treatment with curcumin and the combined treatment. The gene expression analysis results indicated that both Curcumin and Cisplatin decrease the expression of Cdc42 gene, moreover, their co-administration showed synergic effects. Therefore, Curcumin could be an appropriate option for complementary administration with other chemotherapy agents in order to reduce their efficient dose, and to reduce their side effects.
 
 
Full-Text [PDF 431 kb]   (1120 Downloads)    
Type of Study: Original Article | Subject: Cell and Molecular Biology
Received: 2020/09/22 | Revised: 2022/01/18 | Accepted: 2021/08/25 | Published: 2022/01/17 | ePublished: 2022/01/17

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



© 2024 CC BY-NC 4.0 | Nova Biologica Reperta

Designed & Developed by : Yektaweb